Top

Published in:

01-04-2010 | Special Feature

Predicting responses to chemotherapy in breast cancer: from bench to bedside

Author: Sadako Akashi-Tanaka

Published in: Breast Cancer | Issue 2/2010

Abstract

Recent progress in biotechnology, notably microarray analyses, makes it possible to examine the genome-based characteristics of tumors with different prognoses and predict responses to chemotherapy. Furthermore, pharmacogenomic techniques are expected to predict the optimal regimen for individual patients that will provide high benefits with reduced toxicity. Some predictive or prognostic tests for breast cancer are now moving from bench to bedside.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclassed with clinical implications. Proc Natl Acad Sci. 2001;98(19):10869–74.CrossRefPubMed

Nielsen TO, Hsu FD, Jensen K, Maggie K, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.CrossRefPubMed

Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27(8):1168–76.CrossRefPubMed

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–34.CrossRefPubMed

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–7.CrossRefPubMed

Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008;13(5):477–93.CrossRefPubMed

van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. N Engl J Med. 2002;415:530–6.

http://www.eortc.be/services/unit/mindact/MINDACT_websiteii.asp.

Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009: Feb 13 [Epub ahead of print]

10.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312.CrossRefPubMed

11.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.CrossRefPubMed

12.

http://www.cancer.gov/clinicaltrials/digestpage/TAILORx.

13.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–34.CrossRefPubMed

14.

Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23(29):7265–77.CrossRefPubMed

15.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. Expression of the 21 genes in the recurrence score assay and tamoxifen clinical benefit in the NSABP study B-14 of node-negative, estrogen receptor-positive breast cancer. In: Proceedings of ASCO. 2005 (Abstract #510).

16.

Akashi-Tanaka S, Shimizu C, Ando M, Shibata T, Katsumata N, Kouno T, et al. 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. Breast. 2009 Apr 30 [Epub ahead of print]

17.

Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23(16):3676–85.CrossRefPubMed

18.

Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer. 2006;94(2):247–52.CrossRefPubMed

19.

Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26(11):1789–96.CrossRefPubMed

20.

Shimizu C, Tamura K, Koizumi F, Aogi K, Kinoshita T, Fujiwara Y. Immunoglobulin G fragment C gamma receptor (FCGR) polymorphism and efficacy of single -agent trsastuzumab in patients treated with metastatic breast cancera. San Antonio Breast Cancer Symposium. 2008:#6073.

21.

Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19:2334–56.PubMed

22.

Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90(18):1346–60.CrossRefPubMed

23.

Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90(18):1361–70.CrossRefPubMed

24.

Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol. 2008;26(31):5027–35.CrossRefPubMed

25.

Dhesy-Thind B, Pritchard KI, Messersmith H, O’Malley F, Elavathil L, Trudeau M. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat. 2008;109(2):209–29.CrossRefPubMed

26.

Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. 2008;100(1):14–20.PubMedCrossRef

27.

O’Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2009;101(9):644–50.CrossRefPubMed

28.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, et al. on behalf of the BCIRG 006 Investigators. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) withdoxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat. 2005;94 Suppl 1 (Abstract 1).

29.

http://www.clinicaltrials.gov/ct2/show/NCT00689156.

30.

http://www.cancer.gov/clinicaltrials/NSABP-B-36.

31.

http://www.clinicaltrials.gov/ct2/show/study/NCT00801411.

32.

Di Leo A, Isola J, Piette F, Ejlersten B, Pritchard KI, Bartlett JMS, et al. A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. In: 31st San Antonio Breast Cancer Symposium 2008:#705.

33.

Rouzier R, Rajan P, Wagner P, Hess KR, Gold DL, Stec J, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci. 2005;102:8315–20.CrossRefPubMed

34.

McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008;1785(2):96–132.PubMed

35.

Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci. 2006;97(9):813–20.CrossRefPubMed

36.

Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol. 2005;23(3):422–31.CrossRefPubMed

37.

Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362(9381):362–9.CrossRefPubMed

38.

Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, et al. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2006;99(1):9–17.CrossRefPubMed

39.

Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, et al. RPN2 gene confers docetaxel resistance in breast cancer. Nat Med. 2008;14(9):939–48.CrossRefPubMed

40.

Zembutsu H, Suzuki Y, Sasaki A, Tsunoda T, Okazaki M, Yoshimoto M, et al. Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. Int J Oncol. 2009;34(2):361–70.PubMed

Title: Predicting responses to chemotherapy in breast cancer: from bench to bedside
Author: Sadako Akashi-Tanaka
Publication date: 01-04-2010
Publisher: Springer Japan
Published in: Breast Cancer / Issue 2/2010
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-009-0166-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Ultrasound findings and histological features of ductal carcinoma in situ detected by ultrasound examination alone

Malignant neoplasm in the axilla of a male: suspected primary carcinoma of an accessory mammary gland

Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society

Paclitaxel as a first-line chemotherapy for Japanese women with advanced or recurrent breast cancer: a multi-institutional practice-based study by the Kyushu Breast Cancer Study Group (KBC-SG)

Tumor reduction rate predicts early recurrence in patients with breast cancer failing to achieve complete response to primary chemotherapy

Intracystic invasive papillary carcinoma of the male breast with analyses of loss of heterozygosity on chromosome 16q

Keynote webinar | Spotlight on antibody–drug conjugates in cancer